AMX0035 and Progressive Supranuclear Palsy

Summary

A35-009 (ORION) is a Phase 2b/3 trial to evaluate the efficacy and safety of AMX0035 in participants with Progressive Supranuclear Palsy (PSP), consisting of randomized, double blind placebo controlled phases, followed by an optional open-label extension phase.

Timeline

Start

2023-12-21

Primary completion

2025-09-30

Completion

2025-10-21

Drugs

Indications